Evidence map›Paper›PMID 31452347›Full record

ArticleThoracic cancer2019

Diffuse large B-cell lymphoma in a patient with dermatomyositis-associated interstitial lung disease: A case report.

Shan Li, Yuxin Sun, Chi Shao, Kai Xu, Hui Huang

Open access · goldAbstract readCase Reports
In one paragraph

Article in Thoracic cancer, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shan LiDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Yuxin SunDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Chi ShaoDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Kai XuRadiological Department, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Hui HuangDepartment of Pulmonary and Critical Care Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.ORCID 0000-0001-7184-0005
Chinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 63-year-old man presented to our clinic complaining of cough and exertional dyspnea. He was diagnosed with dermatomyositis-associated interstitial lung disease (DM-ILD) with typical rashes, an elevated creatine kinase level and chest high-resolution computed tomography (CT) manifestations. His symptoms and lung shadows improved after treatment with corticosteroids, immunosuppressants and pirfenidone, although his serum creatine kinase level remained elevated. An expanding nodule in the lower left lung and lymphadenopathy in the right cardiophrenic angle were visible on the repeated chest CT scan during follow-up approximately one year later. Empirical antibiotics had no effect. A positron emission tomography-computed tomography (PET-CT) scan showed an increased standard uptake value (SUV) in the newly emerged pulmonary nodule, mediastinal lymphadenopathy and multiple hepatic masses. He was diagnosed with diffuse large B-cell lymphoma following liver biopsy. After eight cycles of rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) chemotherapy, the lymphoma was cured clinically, and his interstitial lung disease (ILD) had improved. Tumor surveillance should be performed during DM-ILD follow-up, and rituximab could be a promising choice for DM-ILD concurrent with lymphoma.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBiopsyCyclophosphamideDermatomyositisDoxorubicinHumansLung Diseases, InterstitialLymphoma, Large B-Cell, DiffuseMaleMiddle AgedPositron Emission Tomography Computed TomographyPrednisoneRituximabTomography, X-Ray ComputedTreatment OutcomeVincristineCyclophosphamideDoxorubicinPrednisoneR-CHOP protocolRituximabVincristineDermatomyositisidiopathic inflammatory myositisinterstitial lung diseaselymphomamalignancy

Identifiers

PMID31452347
PMCPMC6775007
OpenAlexW2971195410

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.